POS1416 THE IMPACT OF NON-PERSISTENCE ON RESOURCE UTILIZATION COSTS IN IMMUNE-MEDIATED RHEUMATIC DISEASES

Background: Rheumatoid arthritis (RA), psoriatic (PsA) and ankylosing spondylitis (AS) are chronic progressive immune-mediated rheumatic diseases (IMRD) that can cause a disability joint deformation thus impact in healthcare resource utilization (HCRU) costs. Objectives: To describe the HCRU treatment costs IMRD patients initiating subcutaneous tumour necrosis factor-alpha inhibitors (SC-TNFi) therapy, based on persistence. Methods: Retrospective cohort study including all naïve SC-TNFi therapy for from 2015-2018 tertiary university hospital. Patients were divided into two cohorts: persistent non-persistent. Treatment persistence was estimated as duration of time initiation to discontinuation during one year follow-up. (outpatient care, rheumatology specialized outpatient inpatient emergency laboratory testing other non- biological therapies) calculated before after compared between non-persistence groups. Results: 110 identified. Baseline characteristics: Non-persistent (n=25) versus Persistent (n=85): median age 48.6(12.7) vs 47.3(15.4) (p=0.692). Female (n=12;48%) (n=49;57.6%) (p=0.493). Race: Caucasian (n=22;88%), Asiatic (n=3;12%), Other (n=0;0%) (n=75;88.2%), (n=5;5.9%), (n=5;5.9%) (p=0.351).IMRD: RA (n=14;56%),PsA (n=2;8%), AS (n=4;16%), spondyloarthropathy (n=5;20%) (n=34;40%),PsA (n=11;12.9%), (n=24;28.3%), (n=16;18.8%) (p=0.470). therapy: adalimumab etanercept commercial biosimilar1 (n=5;20%), biosimilar2 golimumab certolizumab (n=2;8%) (n=22;25.9%), (n=7;8.3%), (n=10;11.8%), (n=24;28.2%), (n=11;12.9%) (p=0.398). Overall cost treatment: 11218.81€ (6444.32), 10470.19€ (3465.48); p= 0.658. Table 1. Non-persistent(n=25) Persistent(n=85) Total(n=110) P 12 months prior initiation,€(SD) Outpatient care 243.48(828.86) 87.17(293.61) 122.70(471.20) 0.204 Rheumatology 216.39(169.88) 174.79(101.06) 184.24(120.55) 0.224 Inpatient 500.41(1542.93) 170.34(846.47) 245.36(1046.74) 0.571 Emergency 37.77(66.00) 39.30(83.16) 38.95(79.31) 0.850 Laboratory 376.12(195.59) 388.20(207.07) 385.46(203.70) 0.458 non-biological therapies 10.77(39.83) 36.79(250.55) 30.88(221.01) 0.803 Total 1384.94(1816.17) 896.60(1247.60) 1007.59(1402.87) 0.299 post 106.11 (172.85) 76.67 (112.90) 83.36 (128.67) 0.682 327.29(170.10) 195.58(100.05) 225.52(130.99) <0.001 89.35(446.77) 80.86(466.54) 82.79(460.11) 0.969 89.14(171.89) 36.06(106.23) 48.12(125.31) 0.198 182.14(128.62) 146.86(141.48) 154.88(138.89) 0.061 3859.80(4043.86) 25.89(116.05) 897.24(2493.21) 4653.84(4269.61) 561.93(682.14) 1491.91(2709.23) Conclusion: - Non-persistence observed less than quarter patients. No differences non-persistent groups, leading us believe may not be associated with offsets IMRD. During period initiation, rheumatologic well total statistically significantly lower cohort. These results suggest savings Disclosure Interests: None declared